Las Vegas, NV -- (SBWIRE) -- 10/10/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Mad Catz Interactive, Inc. (USA) (NYSEMKT: MCZ), Affymax, Inc. (OTCMKTS: AFFY), StemCells Inc (NASDAQ:STEM), ImmunoCellular Therapeutics Ltd (NYSEMKT: IMUC)
Mad Catz Interactive, Inc. (USA) (NYSEMKT: MCZ) managed to keep its fall at -9.32% on above-normal volume of 1.15M shares. The stock settled at $0.680 after floating in a range of $0.67 to $0.75. Its latest price has reached market capitalization of $43.16 million. Its 52-week range has been $0.36 to $0.89. Mad Catz Interactive, Inc. (Mad Catz) designs, manufactures (through third parties in Asia), markets, sells and distributes accessories for all videogame platforms, the personal computer (PC) and Mac and, smart phones and other smart devices.
Has MCZ Found The Bottom and Ready To Move Up? Find Out Here
Affymax, Inc. (OTCMKTS: AFFY) traded down on a volume of 1.14 million, higher than its standard daily volume. Shares have dropped-1.64% to $1.20. Over the last twelve months, the stock has lost-94.73% and faced a worst price of $1.14. Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions.
Has AFFY Found The Bottom And Ready To Gain Momentum? Find Out Here
StemCells Inc (NASDAQ:STEM) settled -2.10% lower at $1.40 on above-normal volume of 1.14M shares during the last trading day. The stock has its 12-month high at $2.50 and 52-week low price was $1.37. It traded in a range of $1.38 to $1.46 during the last trading day. StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry.
Will STEM Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, ImmunoCellular Therapeutics Ltd (NYSEMKT: IMUC) was down on high volume, trading at a volume of 1.36M versus its average daily volume of 670,068.00 shares. At $2.50, the stock has attained market capitalization of 1.36.49 million. mmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain.
Why Should Investors Buy IMUC After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)